ClinConnect ClinConnect Logo
Search / Trial NCT04252547

Effect of Kangaroo Care on Test Weighing

Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Jan 31, 2020

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Kangaroo Care Test Weighing Heart Rate Oxygen Saturation Preterm Infants

ClinConnect Summary

This clinical trial is studying the effects of Kangaroo Care, which is a method where a parent holds their baby skin-to-skin, on weight gain, oxygen levels, and heart rate in premature infants. The researchers want to see how this comforting practice during feeding times can help babies thrive while they are in the neonatal intensive care unit (NICU). In the trial, infants will be randomly divided into two groups. One group will receive Kangaroo Care during their first feeding, while the other group will have it during their second feeding. Both groups will be breastfed by their mothers.

To participate in this study, infants must be born between 26 to 36 weeks of pregnancy, weigh at least 1500 grams, and have started oral feeding. They should not have any serious health issues that could affect feeding. Parents who agree to take part will help their babies experience Kangaroo Care during the study. This trial is currently recruiting participants, and it aims to provide valuable insights into how nurturing practices can support the health and growth of premature infants.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • - Agreeing to participate in the study for parents.
  • The inclusion criteria for infants were as follows;
  • Attaining to oral feeding by the physician in the neonatal intensive care unit
  • Being born at 26-36+6 gestational week which is determined according to the mother's last period cycle
  • Being at 32-39+6 postmenstrual week during the time they are included in the study
  • Having body weight of 1500 grams and above
  • Being breastfed at least once
  • Having no health problems other than being preterm
  • Exclusion Criteria:
  • The exclusion criteria for infants were as follows;
  • Suffering from gastrointestinal, neurological or genetic diseases (such as necrotizing enterocolitis, intracranial bleeding, hydrocephalia, omphalocele, down syndrome, gastroschisis) and other diseases
  • Having a condition obstructing oral feeding (such as cleft palate, cleft lip, facial muscle paralysis, craniofacial abnormalities etc.)
  • Receiving oxygen support

About Istanbul University Cerrahpasa

Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.

Locations

Istanbul, Beykoz, Turkey

Patients applied

0 patients applied

Trial Officials

Duygu Gözen, Assoc. Prof.

Principal Investigator

Istanbul University Cerrahpaşa Florence Nightingale Faculty of Nursing

Ayhan Taştekin, prof.

Principal Investigator

Istanbul Medipol University, Pediatrics

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials